Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
In the SURPASS clinical trial program for type 2 diabetes, diarrhea occurred in approximately 12-16% of patients receiving tirzepatide across various doses (5 mg, 10 mg, and 15 mg weekly), compared to lower rates in comparator groups
What they did: Obese mice received AOD-9604 orally (via gavage) for 14 days at various doses (50, 250, 500 g/kg)
Tirzepatide is a first-in-class T2D medication that activates both the GIP and GLP-1 receptors to help patients better manage blood sugar, while triggering weight loss and improving lipid markers
doi:10.1016/j.pcad.2023.02.005 Lloyd-Jones DM, Allen NB, Anderson CAM, et al
US$ 27.32
US$ 24.98
US$ 27.88
US$ 29.54
US$ 24.27
